Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase

Acta Pharmacologica Sinica

Volumn 29, Issue 10, 2008, Pages 1261-1267

  Du, Li ^a   Zhao, Ya Xue ^b   Yang, Liu Meng ^c   Zheng, Yong Tang ^c   Tang, Yun ^b   Shen, Xu ^a,b   Jiang, Hua Liang ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

HIV 1 integrase inhibitor; Molecular docking; Site directed mutagenesis; Surface plasma resonance

Indexed keywords

1 PYRROLIDINEACETAMIDE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE INHIBITOR; LYSINE; N, N' (METHYLENE DI 4,1 PHENYLENE) BIS 1 PYRROLIDINEACETAMIDE; THREONINE; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; COMPETITIVE INHIBITION; DRUG CYTOTOXICITY; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE; NUCLEOTIDE SEQUENCE; SITE DIRECTED MUTAGENESIS; SURFACE PLASMA RESONANCE;

ACETAMIDES; ANTI-HIV AGENTS; BINDING SITES; DNA, VIRAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PLASMIDS; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53749088987     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00863.x     Document Type: Article

References (36)

1. Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res 1999 52 : 351 69.
2. Cara A, Guarnaccia F, Reitz MS, Gallo RC, Lori F. Self-limiting, cell type-dependent replication of an integrase-defective human immunodeficiency virus type 1 in human primary macrophages but not T lymphocytes. Virology 1995 208 : 242 8.
3. Pommier Y, Neamati N. Inhibitors of human immunodeficiency virus integrase. Adv Virus Res 1999 52 : 427 58.
4. Sherman PA, Fyfe JA. Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc Natl Acad Sci USA 1990 87 : 5119 23.
5. LaFemina RL, Callahan PL, Cordingley MG. Substrate specificity of recombinant human immunodeficiency virus integrase protein. J Virol 1991 65 : 5624 30.
6. Bushman FD, Craigie R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc Natl Acad Sci USA 1991 88 : 1339 43.
7. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005 4 : 236 48.
8. Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr Top Med Chem 2004 4 : 965 77.
9. Cai M, Zheng R, Caffrey M, Craigie R, Clore GM, Gronenborn AM. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol 1997 4 : 567 77.
10. Wang JY, Ling H, Yang W, Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. Embo J 2001 20 : 7333 43.
11. Dayam R, Deng J, Neamati N. HIV-1 integrase inhibitors: 2003-2004 update. Med Res Rev 2006 26 : 271 309.
12. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000 287 : 646 50.
13. Cotelle P. Patented HIV-1 integrase inhibitors (1998-2005). Recent Pat Anti-infect Drug Disc 2006 1 : 1 15.
14. Johnson AA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr Top Med Chem 2004 4 : 1059 77.
15. Drake RR, Neamati N, Hong H, Pilon AA, Sunthankar P, Hume SD, et al. Identification of a nucleotide binding site in HIV-1 integrase. Proc Natl Acad Sci USA 1998 95 : 4170 5.
16. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008 82 : 764 74.
17. Savarino A. In-silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 2007 4 : 21.
18. Jenkins TM, Engelman A, Ghirlando R, Craigie R. A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J Biol Chem 1996 271 : 7712 8.
19. Du L, Shen L, Yu Z, Chen J, Guo Y, Tang Y, et al. Hyrtiosal, from the marine sponge Hyrtios erectus, inhibits HIV-1 integrase binding to viral DNA by a new inhibitor binding site. Chem Med Chem 2008 3 : 173 80.
20. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988 20 : 309 21.
21. Johnson VA, Byington RE. Quantitative assays for virus infectivity. New York : Srockton Press 1990.
22. Wang Q, Wang YT, Pu SP, Zheng YT. Zinc coupling potentiates anti-HIV- 1 activity of baicalin. Biochem Biophys Res Commun 2004 324 : 605 10.
23. Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 1980 36 : 3219 28.
24. Clark M, Cramer R, van Opdebosch N. Validation of the general purpose Tripos 5.2 force field. J Comput Chem 1989 10 : 982 1012.
25. Sybyl (Computer program). Version 7.0. St Louis, MO : Tripos Associates Inc 2004.
26. Berman HM, Bhat TN, Bourne PE, Feng Z, Gilliland G, Weissig H, et al. The Protein Data Bank and the challenge of structural genomics. Nat Struct Biol 2000 7 Suppl : 957 9.
27. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA 1999 96 : 13 040 3.
28. Weiner SJ, Kollman PA, Nguyen DT, Case DA. An all atom force field for simulations of proteins and nucleic acid. J Comput Chem 1986 11 : 431 9.
29. Weiner SJ, Kollman PA, Case DA, Singh C, Ghio G, Alagona S, et al. New force field for molecular mechanical simulation of nucleic acids and proteins. J Am Chem Soc 1984 106 : 765 84.
30. Rosin CD, Belew RK, Morris GM, Olson AJ, Goodsell DS. Computational coevolution of antiviral drug resistance. Artif Life 1998 4 : 41 59.
31. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins 2003 52 : 609 23.
32. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997 267 : 727 48.
33. Shkriabai N, Patil SS, Hess S, Budihas SR, Craigie R, Burke TR Jr., et al. Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry. Proc Natl Acad Sci USA 2004 101 : 6894 9.
34. Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR Jr., et al. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem 2002 277 : 12 596 603.
35. Merck. Monogram and Merck to collaborate on phase III trials of Merck's investigational HIV-1 integrase inhibitor. [Cited 07 Sep 2007] Available from URL : http://www.hivandhepatitis.com/re-cent/2007/090707_a.html.
36. Li HY, Zawahir Z, Song LD, Long YQ, Neamati N. Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. J Med Chem 2006 49 : 4477 86.